



FINAL REPORT

Bill No.	: MGMWPR240092225	Bill Date	: 14-10-2024 11:02
Patient Name	: MR. KIRAN BHAGWAN TAWARE	UHID	: MGM240017131
Age / Gender	: 56 Yrs 2 Mth / MALE	Patient Type	: IPD
Ref. Consultant	: DR.PRASHANT ATHALE	Ward	: SICU
Sample ID	: MGM24153534	Current Bed	: SICU-011
IP Number	: MGMIP2406720	Reporting Date & Time	: 17-10-2024 15:28
		Receiving Date & Time	: 14/10/2024 11:17

Microbiology Report

BLOOD - C/S - 2 - BAC ALERT

Specimen : Blood
 Site : Arterial site
 Remarks : Central & Peripheral site shows No growth after 3 days of incubation.
 Organism : Acinetobacter baumannii

ANTIBIOTICS	INTERPRETATION	MIC
Amikacin	RESISTANT	>=64
Amoxicillin/Clavulanic acid	RESISTANT	Disc diffusion
Cefotaxime	RESISTANT	Disc diffusion
Ceftriaxone	RESISTANT	Disc diffusion
Cefuroxime	RESISTANT	Disc diffusion
Cefoperazone	RESISTANT	>=64
Ceftazidime	SENSITIVE	<=1
Gentamicin	SENSITIVE	Disc diffusion
Netilmicin	SENSITIVE	>=4
Ciprofloxacin	RESISTANT	Disc diffusion
Levofloxacin	RESISTANT	
Trimethoprim/Sulphamethoxazole	RESISTANT	160
Piperacillin/Tazobactam	RESISTANT	>=128
Colistin	SENSITIVE	<=0.5
Cefepime	RESISTANT	>=32
Imipenem	RESISTANT	>=16
Meropenem	RESISTANT	>=64
Cefaperazone/Sulbactam	RESISTANT	Disc diffusion
Ticarcillin/Clavulanic acid	RESISTANT	
Polymyxin B	SENSITIVE	1
Tigecycline	SENSITIVE	<=0.5
Minocycline	SENSITIVE	<=0.5

Method :- Culture- Aerobic by Automated BACT/ ALERT 3D. Identification done by Biochemical reactions / Automated Vitek-2 . Antimicrobial sensitivity by automated Vitek -2 / conventional methods/estrips.

Note :-

- Result of culture and antimicrobial susceptibility test need to be correlated clinically.
- Previous history of antibiotic usage may influence the growth of microorganisms in vitro.
- Antibiotic susceptibility done as per revised CLSI Guidelines.

Clinical Reference :

- CLSI: Performance standards for Antimicrobial Susceptibility Testing.

End of the Report